Leukocyte chemoattractant receptor FPR2 may accelerate atherogenesis

Medical Hypotheses

Volumn 79, Issue 1, 2012, Pages 101-103

  Wan, Wuzhou ^a   Gao, Ji Liang ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMYL PEPTIDE RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROGENESIS; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; HUMANS; LEUKOCYTES; MONOCYTES; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SUPEROXIDES;

EID: 84861461593     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.014     Document Type: Article

References (18)

1. Roger V.L., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
2. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
3. Zernecke A., Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010, 86:192-201.
4. Ye R.D., et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009, 61:119-161.
5. Lavigne M.C., Murphy P.M., Leto T.L., Gao J.L. The N-formyl peptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils. Cell Immunol 2002, 218:7-12.
6. Madamanchi N.R., Runge M.S. NADPH oxidases and atherosclerosis: unraveling the details. Am J Physiol Heart Circ Physiol 2010, 298:H1-H2.
7. Kosuge M., et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J 2007, 71:186-190.
8. Dong Z., et al. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 2011, 17:1357-1364.
9. Su S.B., Gong W., Gao J.L., Shen W., Murphy P.M., Oppenheim J.J., et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999, 189:395-402.
10. Koenen R.R., Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 2011, 3:713-725.
11. Apostolakis S., Amanatidou V., Spandidos D.A. Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias. Acta Pharmacol Sin 2010, 31:1103-1110.
12. Lee H.Y., et al. Serum amyloid A induces CCL2 production via formyl peptide receptor like 1-mediated signaling in human monocytes. J Immunol 2008, 181:4332-4339.
13. Lee H.Y., Kim S.D., Shim J.W., Yun J., Kim K., Bae Y.S. Activation of formyl peptide receptor like-1 by serum amyloid A induces CCL2 production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2009, 380:313-317.
14. Boisvert W.A., Curtiss L.K., Terkeltaub R.A. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000, 21:129-137.
15. He R., Sang H., Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003, 101:1572-1581.
16. Chiang N., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-487.
17. Dufton N., et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010, 184:2611-2619.
18. Chen K., et al. A critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol 2010, 184:3331-3335.